Treprostinil Attains Clinically Therapeutic Concentrations in Neonates with Pulmonary Hypertension on Extracorporeal Membrane Oxygenation Support

INTRODUCTION Treprostinil is a prostacyclin analog used for treatment of pulmonary hypertension (PH) in adults and children, currently awaiting clinical assessment for use in neonates. OBJECTIVES We aimed to investigate the use of treprostinil in neonates with PH on extracorporeal membrane oxygenation (ECMO) support and measure plasma concentrations of the drug. METHODS This is a retrospective case-series with prospectively collected blood samples, conducted in a quaternary care neonatal intensive care unit. Brain natriuretic peptide, cardiac function on Doppler echocardiography and the occurrence of adverse effects was monitored. Plasma concentrations were measured using high performance liquid chromatography and mass spectrometry. RESULTS Four patients with PH requiring ECMO therapy were studied. Treprostinil doses of 20 - 58 ng/kg/min reached concentrations of 0.99 - 4.39 ng/mL and induced clinical improvement. Infusion of treprostinil was associated with improved right ventricular function, reversed right-to-left shunting through the ductus arteriosus, and stable or decreasing need for vasopressor support. No adverse effects were observed. CONCLUSION This is the first study to report clinically therapeutic treprostinil concentrations in circulating plasma following treprostinil administration in neonates on ECMO, with associated clinical improvement of PH and no signs of hemodynamic instability.

[1]  K. Barrington,et al.  Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. , 2019, The Cochrane database of systematic reviews.

[2]  D. Tibboel,et al.  Drug Disposition and Pharmacotherapy in Neonatal ECMO: From Fragmented Data to Integrated Knowledge , 2019, Front. Pediatr..

[3]  J. Feinstein,et al.  Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. , 2019, Journal of cardiovascular pharmacology.

[4]  B. Hanna,et al.  Treprostinil Improves Persistent Pulmonary Hypertension Associated with Congenital Diaphragmatic Hernia , 2018, The Journal of pediatrics.

[5]  P. Tourneux,et al.  Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension. , 2017, Journal of pediatric surgery.

[6]  S. Lombardi,et al.  Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension , 2017, Pulmonary circulation.

[7]  B. Lake,et al.  Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages , 2017, Drug Metabolism and Disposition.

[8]  S. Morton,et al.  Fetal Physiology and the Transition to Extrauterine Life. , 2016, Clinics in perinatology.

[9]  S. Berkelhamer,et al.  Persistent pulmonary hypertension of the newborn , 2015, Maternal Health, Neonatology and Perinatology.

[10]  L. Lusk,et al.  Short-Term Treprostinil Use in Infants with Congenital Diaphragmatic Hernia following Repair. , 2015, The Journal of pediatrics.

[11]  J. Fraser,et al.  Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study , 2015, Critical Care.

[12]  B. Hanna,et al.  Safety of Epoprostenol and Treprostinil in Children Less than 12 Months of Age , 2013, Pulmonary circulation.

[13]  D. Tibboel,et al.  Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). , 2012, Current drug metabolism.

[14]  D. Tibboel,et al.  Determinants of drug absorption in different ECMO circuits , 2010, Intensive Care Medicine.

[15]  R. Benza,et al.  Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion , 2008, Journal of clinical pharmacology.

[16]  R. Benza,et al.  Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.

[17]  T. Hunt,et al.  Pharmacokinetics of Treprostinil Sodium Administered by 28‐Day Chronic Continuous Subcutaneous Infusion , 2004, Journal of clinical pharmacology.

[18]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[19]  J. Tyson,et al.  Persistent Pulmonary Hypertension of the Newborn in the Era Before Nitric Oxide: Practice Variation and Outcomes , 2000, Pediatrics.

[20]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.